EDIT Key Statistics, Chart & Performance
The current stock price of EDIT is 2.11 USD. In the past month the price decreased by -31.05%. In the past year, price decreased by -1.4%.
EDIT Latest News, Press Relases and Analysis
EDIT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.55B | ||
| AMGN | AMGEN INC | 15.47 | 182.20B | ||
| GILD | GILEAD SCIENCES INC | 15.13 | 153.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.95 | 109.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.49 | 77.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 911.63 | 61.42B | ||
| INSM | INSMED INC | N/A | 44.06B | ||
| NTRA | NATERA INC | N/A | 32.66B | ||
| BIIB | BIOGEN INC | 10.76 | 26.43B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.97 | 20.42B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About EDIT
Company Profile
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 246 full-time employees. The company went IPO on 2016-02-03. The company has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. The company is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.
Company Info
EDITAS MEDICINE INC
11 Hurley St
Cambridge MASSACHUSETTS 02141 US
CEO: James C. Mullen
Employees: 246
Phone: 16174019000
EDITAS MEDICINE INC / EDIT FAQ
Can you describe the business of EDITAS MEDICINE INC?
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 246 full-time employees. The company went IPO on 2016-02-03. The company has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. The company is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.
What is the stock price of EDITAS MEDICINE INC today?
The current stock price of EDIT is 2.11 USD. The price decreased by -3.65% in the last trading session.
Does EDITAS MEDICINE INC pay dividends?
EDIT does not pay a dividend.
What is the ChartMill technical and fundamental rating of EDIT stock?
EDIT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for EDIT stock?
EDITAS MEDICINE INC (EDIT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.38).
What is EDITAS MEDICINE INC worth?
EDITAS MEDICINE INC (EDIT) has a market capitalization of 205.98M USD. This makes EDIT a Micro Cap stock.
EDIT Technical Analysis
EDIT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to EDIT. EDIT has a bad profitability rating. Also its financial health evaluation is rather negative.
EDIT Financial Highlights
Over the last trailing twelve months EDIT reported a non-GAAP Earnings per Share(EPS) of -2.38. The EPS increased by 7.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -99.05% | ||
| ROE | -1485.43% | ||
| Debt/Equity | 4.02 |
EDIT Forecast & Estimates
20 analysts have analysed EDIT and the average price target is 4.03 USD. This implies a price increase of 90.95% is expected in the next year compared to the current price of 2.11.
For the next year, analysts expect an EPS growth of 27.22% and a revenue growth -49.61% for EDIT